Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
0.00
0.00 (0.00%)
Mar 24, 2026, 9:30 AM EDT - Market open
Aytu BioPharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Aytu BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $9.33, which forecasts no change in the stock price over the next year. The lowest target is $7.00 and the highest is $13.
Price Target: $9.33 (0.00%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2025.
Analyst Ratings
The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $13 → $13 | Strong Buy | Maintains | $13 → $13 | n/a | Dec 10, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | n/a | Sep 25, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | n/a | Sep 25, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | n/a | Jul 1, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | n/a | Jun 30, 2025 |
Financial Forecast
Revenue This Year
57.76M
from 66.38M
Decreased by -12.99%
Revenue Next Year
83.02M
from 57.76M
Increased by 43.75%
EPS This Year
-1.68
from -2.16
EPS Next Year
-0.52
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 64.1M | 107.3M | |
| Avg | 57.8M | 83.0M | |
| Low | 51.9M | 68.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.5% | 85.8% | |
| Avg | -13.0% | 43.7% | |
| Low | -21.7% | 18.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.14 | 0.04 | |
| Avg | -1.68 | -0.52 | |
| Low | -2.17 | -1.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.